354 related articles for article (PubMed ID: 23448264)
1. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
2. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR
Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303
[TBL] [Abstract][Full Text] [Related]
4. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes.
Chen KC; Cheng TL; Leu YL; Prijovich ZM; Chuang CH; Chen BM; Roffler SR
Cancer Gene Ther; 2007 Feb; 14(2):187-200. PubMed ID: 16977328
[TBL] [Abstract][Full Text] [Related]
5. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
6. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
[TBL] [Abstract][Full Text] [Related]
7. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
Huang PT; Chen KC; Prijovich ZM; Cheng TL; Leu YL; Roffler SR
Cancer Gene Ther; 2011 Jun; 18(6):381-9. PubMed ID: 21350582
[TBL] [Abstract][Full Text] [Related]
10. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT.
Tietze LF; Schmuck K; Schuster HJ; Müller M; Schuberth I
Chemistry; 2011 Feb; 17(6):1922-9. PubMed ID: 21274943
[TBL] [Abstract][Full Text] [Related]
12. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
13. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
Bosslet K; Czech J; Hoffmann D
Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
[TBL] [Abstract][Full Text] [Related]
14. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of β-glucuronidase activity by an activity-based 124I-trapping probe for the personalized glucuronide prodrug targeted therapy.
Su YC; Cheng TC; Leu YL; Roffler SR; Wang JY; Chuang CH; Kao CH; Chen KC; Wang HE; Cheng TL
Mol Cancer Ther; 2014 Dec; 13(12):2852-63. PubMed ID: 25277385
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.
Prijovich ZM; Chen BM; Leu YL; Chern JW; Roffler SR
Br J Cancer; 2002 May; 86(10):1634-8. PubMed ID: 12085215
[TBL] [Abstract][Full Text] [Related]
17. Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors.
Bernt KM; Steinwaerder DS; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2002 Nov; 62(21):6089-98. PubMed ID: 12414633
[TBL] [Abstract][Full Text] [Related]
18. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
[TBL] [Abstract][Full Text] [Related]
19. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for sarcoma utilizing adenoviral transfer of the beta-glucuronidase and bax genes and an anthracyline prodrug.
Miller SD; Mohiuddin I; Cao XX; Ozvaran MK; Daniel JC; Roy Smythe W
J Surg Res; 2004 Oct; 121(2):153-8. PubMed ID: 15501454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
